The clinical-stage biopharmaceutical company discussed in today’s article, which is focused on developing innovative cancer therapies, recently saw its stock more than double in a single day on positive phase 3 clinical trial results for its leading pipeline candidate, which the company describes as a “pipeline in a drug”. So, is this stock a buy? For a closer look at this company and what investors need to know, CLICK HERE.
Does This Biopharma Company’s “Pipeline In A Drug” Cancer Therapy Make Its Stock A Buy?
- by Alex Clarke
